Insmed, Inc. (INSM)
121.16
+3.09
(+2.62%)
USD |
NASDAQ |
Nov 13, 16:00
121.16
0.00 (0.00%)
After-Hours: 19:59
Insmed Enterprise Value : 25.50B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 25.50B |
| November 11, 2026 | 26.09B |
| November 10, 2026 | 25.81B |
| November 09, 2026 | 25.07B |
| November 06, 2026 | 24.69B |
| November 05, 2026 | 23.46B |
| November 04, 2026 | 23.73B |
| November 03, 2026 | 22.51B |
| November 02, 2026 | 23.58B |
| October 30, 2026 | 24.29B |
| October 29, 2026 | 24.08B |
| October 28, 2026 | 20.87B |
| October 27, 2026 | 20.43B |
| October 26, 2026 | 20.07B |
| October 23, 2026 | 20.09B |
| October 22, 2026 | 20.45B |
| October 21, 2026 | 20.23B |
| October 20, 2026 | 20.59B |
| October 19, 2026 | 20.50B |
| October 16, 2026 | 20.72B |
| October 15, 2026 | 21.36B |
| October 14, 2026 | 21.05B |
| October 13, 2026 | 20.83B |
| October 12, 2026 | 21.22B |
| October 09, 2026 | 21.67B |
| Date | Value |
|---|---|
| October 08, 2026 | 21.64B |
| October 07, 2026 | 21.92B |
| October 06, 2026 | 22.68B |
| October 05, 2026 | 22.38B |
| October 02, 2026 | 23.97B |
| October 01, 2026 | 23.42B |
| September 30, 2026 | 24.64B |
| September 29, 2026 | 24.83B |
| September 28, 2026 | 25.27B |
| September 25, 2026 | 25.31B |
| September 24, 2026 | 26.12B |
| September 23, 2026 | 25.42B |
| September 22, 2026 | 25.96B |
| September 21, 2026 | 26.00B |
| September 18, 2026 | 25.78B |
| September 17, 2026 | 26.65B |
| September 16, 2026 | 26.34B |
| September 15, 2026 | 25.76B |
| September 14, 2026 | 26.94B |
| September 11, 2026 | 27.83B |
| September 10, 2026 | 27.37B |
| September 09, 2026 | 27.70B |
| September 08, 2026 | 26.85B |
| September 04, 2026 | 27.15B |
| September 03, 2026 | 27.24B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Gilead Sciences, Inc. | 226.62B |
| Incyte Corp. | 21.01B |
| Vertex Pharmaceuticals, Inc. | 137.73B |
| Regeneron Pharmaceuticals, Inc. | 91.75B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -100.32M |
| Revenue (Quarterly) | 524.43M |
| Total Expenses (Quarterly) | 624.75M |
| EPS Diluted (Quarterly) | -0.4585 |
| Gross Profit Margin (Quarterly) | 84.12% |
| Profit Margin (Quarterly) | -19.13% |
| Earnings Yield | -2.32% |
| Normalized Earnings Yield | -2.506 |